Cargando…
Minimal important difference in childhood interstitial lung diseases
BACKGROUND: Monitoring disease progression in childhood interstitial lung diseases (chILD) is essential. No information for the minimal important difference (MID), which is defined as the smallest change in a parameter that is perceived as important prompting a clinician to change the treatment, is...
Autores principales: | Griese, Matthias, Schwerk, Nicolaus, Carlens, Julia, Wetzke, Martin, Emiralioğlu, Nagehan, Kiper, Nural, Lange, Joanna, Krenke, Katarzyna, Seidl, Elias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176404/ https://www.ncbi.nlm.nih.gov/pubmed/36572533 http://dx.doi.org/10.1136/thorax-2022-219206 |
Ejemplares similares
-
Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial
por: Griese, Matthias, et al.
Publicado: (2020) -
ABCA3-related interstitial lung disease beyond infancy
por: Li, Yang, et al.
Publicado: (2023) -
Diagnostic workup of childhood interstitial lung disease
por: Nathan, Nadia, et al.
Publicado: (2023) -
Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease
por: Griese, Matthias, et al.
Publicado: (2022) -
Genomic testing for children with interstitial and diffuse lung disease (chILD): parent satisfaction, understanding and health-related quality of life
por: Kelada, Lauren, et al.
Publicado: (2022)